10.2 Thrombocytopenia & Neutropenia
Key Takeaways
- ITP is antibody-mediated platelet destruction, classically against GPIIb/IIIa or GPIb/IX, with an otherwise normal smear and no schistocytes, distinguishing it from TTP.
- NAIT results from maternal alloantibody, most often anti-HPA-1a, against a paternally inherited platelet antigen the fetus carries, and unlike RhD HDFN it can severely affect a first pregnancy.
- Posttransfusion purpura (PTP) produces severe thrombocytopenia 5-10 days after transfusion in an HPA-1a-negative patient who forms anti-HPA-1a, destroying both donor and the patient's own antigen-negative platelets.
- Heparin-induced thrombocytopenia (HIT) is caused by antibody against platelet factor 4 (PF4)-heparin complexes and, despite the thrombocytopenia, causes a paradoxical thrombosis risk rather than bleeding.
- Neutropenia workup uses ANC thresholds and antineutrophil antibody/HNA testing, and alloimmune neonatal neutropenia mirrors the NAIT mechanism applied to neutrophil antigens.
Immune Thrombocytopenia (ITP)
Immune thrombocytopenic purpura (ITP) is caused by autoantibody, most often against glycoprotein IIb/IIIa or glycoprotein Ib/IX, that opsonizes platelets for splenic macrophage clearance. It can be primary (idiopathic) or secondary to SLE, HIV, or lymphoproliferative disease. Acute ITP is a pediatric, postviral presentation that is usually self-limited; chronic ITP is more typical in adults and often insidious. The peripheral smear is otherwise normal aside from low platelet count and sometimes large platelets reflecting compensatory marrow production - the absence of schistocytes is the key finding that separates ITP from thrombotic microangiopathies such as TTP, which also present with thrombocytopenia but demand urgent, different management (plasma exchange, not platelet transfusion). Treatment includes corticosteroids, IVIG (saturates Fc receptors, slowing platelet clearance), anti-D in Rh-positive, nonsplenectomized patients (by inducing a controlled extravascular hemolytic process that competes for splenic macrophage Fc receptors), TPO-receptor agonists, and splenectomy for refractory disease. Platelet transfusion is generally reserved for active bleeding because transfused platelets are cleared quickly by the same antibody.
Neonatal Alloimmune Thrombocytopenia (NAIT/FNAIT)
Neonatal alloimmune thrombocytopenia (NAIT), also called fetal/neonatal alloimmune thrombocytopenia (FNAIT), is the platelet analog of HDFN: the mother lacks a platelet-specific antigen that the fetus inherits from the father, she forms IgG alloantibody, and it crosses the placenta to destroy fetal platelets. The single most important exam fact is that NAIT can severely affect the first pregnancy, unlike RhD HDFN, because platelet-specific antigens are expressed early in gestation and sensitizing exposure can occur via small fetomaternal hemorrhage earlier and more readily than for RBC antigens. The most commonly implicated antigen is HPA-1a, also called PlA1: the mother is HPA-1a-negative and the father and fetus are HPA-1a-positive. Clinical concern centers on intracranial hemorrhage (ICH) in utero or at birth, which drives prenatal monitoring and, when severe, in-utero IVIG or maternal platelet transfusion planning. Neonatal treatment uses antigen-negative platelets - maternal platelets, washed to remove the causative antibody, are compatible because the mother lacks the antigen - or, when unavailable, random-donor platelets with IVIG to blunt clearance while antigen-negative units are sourced.
Posttransfusion Purpura (PTP)
Posttransfusion purpura (PTP) is a rare but classically tested complication: severe thrombocytopenia developing 5-10 days after a blood transfusion, almost always in a patient who is HPA-1a-negative and has been previously sensitized by pregnancy or a prior transfusion. On re-exposure to HPA-1a-positive platelets in the transfused product, the patient mounts an anamnestic anti-HPA-1a response, but the heavily tested feature is that the antibody destroys the patient's own antigen-negative platelets as well as the transfused antigen-positive ones, through mechanisms involving immune complexes and soluble antigen adsorption onto autologous platelets. First-line treatment is IVIG, or plasma exchange for refractory cases; further transfusion should use HPA-1a-negative products when transfusion cannot be avoided, since even a small transfused volume can retrigger the reaction.
Heparin-Induced Thrombocytopenia and Other Drug-Related Cytopenias
Heparin-induced thrombocytopenia (HIT) is antibody-mediated - IgG against platelet factor 4 (PF4)-heparin complexes - but differs from other immune thrombocytopenias in one crucial way: it causes a paradoxical hyperthrombotic state, not primarily bleeding, because the immune complexes activate platelets. Thrombocytopenia typically appears 5-10 days after heparin exposure, or faster with recent prior exposure. Management stops all heparin products, including flushes, and substitutes a non-heparin anticoagulant; platelet transfusion is generally avoided because it can fuel further thrombosis. Other drugs such as quinine, quinidine, and sulfonamides can cause drug-dependent antiplatelet antibodies through mechanisms analogous to DIIHA.
Neutropenia and Its Immune Workup
Neutropenia is defined by absolute neutrophil count (ANC): mild is 1000-1500/microliter, moderate is 500-1000/microliter, and severe (agranulocytosis) is below 500/microliter, the threshold at which infection risk rises sharply. Immune-mediated neutropenia mirrors the platelet and red cell disorders above. Autoimmune neutropenia of infancy is a usually benign, self-limited pediatric condition with antineutrophil autoantibody. Alloimmune neonatal neutropenia (ANN) follows the NAIT pattern: maternal antibody against paternally inherited human neutrophil antigens (HNA) crosses the placenta and destroys fetal or neonatal neutrophils. Drug-induced agranulocytosis - classic culprits include clozapine, propylthiouracil, and certain antibiotics - can cause abrupt, severe neutrophil loss through hapten or immune-complex mechanisms analogous to DIIHA. Laboratory workup includes serial CBCs with differential, antineutrophil antibody testing by granulocyte agglutination and immunofluorescence assays, HNA typing of parents in suspected ANN, and bone marrow examination when a production defect rather than peripheral destruction is suspected. Because neutrophils are not routinely crossmatched, granulocyte transfusion is reserved for severe, refractory neutropenia with life-threatening infection.
Distinguishing the Cytopenias
| Disorder | Antibody target | Typical timing | Key distinguishing feature |
|---|---|---|---|
| ITP | GPIIb/IIIa or GPIb/IX (platelet) | Any age; acute form in children | Normal smear except low platelets, no schistocytes |
| NAIT | HPA-1a (most common) | In utero or at birth | Can affect the first pregnancy |
| PTP | HPA-1a | 5-10 days post-transfusion | Destroys the patient's own antigen-negative platelets |
| HIT | PF4-heparin complex | 5-10 days post-heparin | Causes thrombosis, not bleeding |
Confirmatory and Supportive Testing
When a platelet-antibody mechanism is suspected, the reference laboratory has several confirmatory tools beyond the platelet count. Platelet antigen genotyping (molecular typing for HPA alleles) on parental samples is the definitive way to confirm an HPA mismatch in suspected NAIT, since serologic platelet antibody identification is technically demanding and often only available at specialized reference centers. Platelet antibody detection assays, such as a monoclonal antibody-specific immobilization of platelet antigens (MAIPA) technique, localize the antibody to a specific glycoprotein rather than just confirming that antiplatelet antibody is present, which is what separates a glycoprotein-specific alloantibody (NAIT, PTP) from the broader, less specific reactivity typical of ITP autoantibodies. For HIT, a PF4-heparin ELISA is used as an initial screen, followed by a functional assay (such as a serotonin-release assay) to confirm that the antibody actually activates platelets, since the ELISA alone has a meaningful false-positive rate and the functional assay carries the diagnostic weight for committing a patient to lifelong heparin avoidance.
Across all four disorders, the SBB exam expects you to link the antibody target to the transfusion decision: ITP rarely requires antigen-matched platelets because the autoantibody is broadly reactive against the patient's own glycoproteins regardless of donor; NAIT and PTP specifically require antigen-negative (HPA-1a-negative) product when transfusion is unavoidable; and HIT requires avoiding platelet transfusion altogether outside of active, life-threatening bleeding because more platelets can fuel the prothrombotic process.
A woman's first pregnancy results in a neonate with severe thrombocytopenia, and the mother has no history of prior transfusion or pregnancy. Testing shows the mother is HPA-1a-negative and the father is HPA-1a-positive. Which statement correctly explains why the first pregnancy was affected?
A patient develops severe thrombocytopenia nine days after receiving a red blood cell transfusion. Testing reveals a strong anti-HPA-1a in the patient's plasma, and the patient's own platelets, which are HPA-1a-negative, are also markedly reduced. What is this presentation, and what is the first-line treatment?
A patient started on heparin nine days ago develops a falling platelet count along with a new deep vein thrombosis. Which mechanism and management best fit this presentation?